Bio-Techne launches HPV assay in Europe

LabPulse.com staff writers
Jul 5, 2022
2020 07 29 23 56 6775 Hpv Infection 400

Bio-Techne on Wednesday announced the European launch and CE-IVD marking of its RNAscope ISH Probe High Risk HPV assay to detect high-risk human papillomavirus (HPV) in oropharyngeal squamous cell carcinoma patients.

RNAscope in situ hybridization (ISH) is a highly sensitive and specific spatial biology technology, Bio-Techne said.

The assay enables users to visualize and localize biomarker expression patterns by light microscopy. It is used in clinical laboratories with the CE-IVD marked Bond RNAscope Brown detection kit on the automated Leica Biosystems Bond-III stainer.

The assay detects high-risk HPV types 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82.

Latest in HPV
Hpv Infection Social
HPV point-of-care test in development combines isothermal amplification, lateral flow detection
June 23, 2023
Lab Woman Dna Social
Roche receives WHO prequalification for HPV screening tool
June 13, 2023
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Head Neck Social
Mayo Clinic, Naveris collaborate to evaluate HPV DNA test in clinical trial
April 13, 2023
Related Stories
Hpv Infection Social
Molecular Diagnostics
HPV point-of-care test in development combines isothermal amplification, lateral flow detection
Lab Woman Dna Social
HPV
Roche receives WHO prequalification for HPV screening tool
Mitochondria Social
Immunoassays
Bio-Techne releases next-generation mitochondrial imaging dyes
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in HPV
HPV point-of-care test in development combines isothermal amplification, lateral flow detection
By LabPulse.com staff writers
A testing platform that combines the two technologies often used separately in diagnostic tests could simplify the equipment and procedures needed for HPV testing.
June 23, 2023
Hpv Infection Social
Roche receives WHO prequalification for HPV screening tool
By LabPulse.com staff writers
Prequalification helps expand access to the screening tool in countries that rely on the WHO's list of prequalified suppliers in making purchasing and implementation decisions.
June 13, 2023
Lab Woman Dna Social
Mailed HPV home test kits doubled cervical cancer screening rates in study
By Elissa Wolfson
Mailing human papillomavirus (HPV) self-collection kits for at-home use improved cervical cancer screening in under-screened, low-income women by nearly two-fold.
May 12, 2023
Hpv Infection Social
Mayo Clinic, Naveris collaborate to evaluate HPV DNA test in clinical trial
By LabPulse.com staff writers
The test is being developed with the aim of aiding treatment selection for patients with HPV-driven head and neck cancer.
April 13, 2023
Head Neck Social
Becton Dickinson HPV assay FDA approved with BD SurePath, Hologic ThinPrep Pap tests
By LabPulse.com staff writers
The BD Onclarity HPV Assay individually tests for an extended set of HPV types, including HPV 31, which poses a higher risk for causing cervical precancer than HPV 18, Becton Dickinson said.
February 21, 2023
Hpv Infection Social
BioReference offering Roche Diagnostics cytology test for women at high risk for HPV
By LabPulse.com staff writers
The test uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results.
February 9, 2023
Hpv Infection Social
Virax Biolabs obtains CE Mark, introduces human papillomavirus test kit
By LabPulse.com staff writers
The HPV test kit covers 18 genotypes of the human papillomavirus, including type 53, which is higher risk and becoming increasingly prevalent.
January 4, 2023
Hpv Infection Social
Enzo launches RNA gene expression platform for HPV
By LabPulse.com staff writers
The platform's products combine sequence-specific probes with Enzo's LoopRNA in situ hybridization (ISH) technology, enabling the products to detect target genes in tissue or cell samples while preserving the morphology, Enzo said. This study of single cells within their native tissue environment, called spatial biology, helps scientists characterize and understand disease, Enzo added.
September 25, 2022
2019 05 17 20 09 8391 Hpv 400
TTS, OmniPathology to offer oral HPV testing in L.A.
By LabPulse.com staff writers
A throat swab enables the detection of 14 high-risk strains of HPV by pathologists at OmniPathology's high-complexity, CLIA-certified pathology laboratory in Pasadena, CA.
August 16, 2022
2019 05 17 20 09 8391 Hpv 400
OmniPathology launches lab-developed test for HPV
By LabPulse.com staff writers
The PCR-based test detects 14 high-risk strains of HPV, a virus with potential to progress to cancer. It is performed on a throat swab submitted for testing to OmniPathology's CLIA-certified laboratory in Pasadena, CA, and helps screen for oropharyngeal cancer and early premalignant lesions.
July 11, 2022
2019 05 15 20 52 2340 Lab Pcr Tubes Dna 400
Roche launches HPV self-sampling solution
By LabPulse.com staff writers
The patient self-collects a sample while at a healthcare facility, following instructions provided by a healthcare worker. Then the clinically validated vaginal sample is analyzed with the Roche Cobas HPV test on one of its molecular instruments.
June 15, 2022
2020 07 29 23 56 6775 Hpv Infection 400
Seegene develops '3 Ct' assay for HPV infection
By LabPulse.com staff writers
The Allplex HPV HR assay detects 14 high-risk HPV types that cause cervical cancer. The assay provides the individual Ct value of each cancer type, allowing quantitative analysis to determine the infection level. The test is expected to be launched in the first half of 2022.
April 26, 2022
2019 05 17 20 09 8391 Hpv 400
Page 1 of 3
Next Page